Atnahs Acquires Naproxen Suspension in the US

Basildon, UK, January 31 2016 – Atnahs Pharma US Limited (“Atnahs”) is pleased to announce the acquisition of Naproxen Suspension from Pediapharm Inc. in a total transaction of US$4.25 million.

The product is currently awaiting Food and Drug Administration (“FDA”) Supplement Approval regarding the manufacturing site transfer.

Atnahs is based in Basildon, Copenhagen, Vadodara and Sydney.
Contact: Amit Patel at info@atnahs.com or +44(0)1268 594777